New TKI Bosutinib Active in Chronic-Phase CML Resistant to Other TKIs
Posting Date: June 04, 2008
Prospective open-label phase I/II study
Summary of Key Conclusions
Novel tyrosine kinase inhibitor (TKI) bosutinib active in patients with chronic-phase chronic myeloid leukemia (CML) with imatinib intolerance, imatinib resistance, or resistance to second-generation TKIs
Bosutinib active in patients with P-loop and non–P-loop mutations
Relatively low rate of hematologic toxicities
Reference
Brümmendorf TH, Cervantes F, Kim DW, et al. Bosutinib (SKI-606) is safe and active in patients with chronic phase (CP) chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Program and abstracts of the 44th American Society of Clinical Oncology Annual Meeting; May 30 - June 3, 2008; Chicago, Illinois. Abstract 7001.
©2008 Clinical Care Options, LLC.